

Phosphoglycerate mutase regulates Treg differentiation through control of serine synthesis and one-carbon metabolism

Reviewed Preprint

v1 • January 30, 2025

Not revised

Wesley H Godfrey, Kaho Cho, Xiaojing Deng, Chandra Shekar R Ambati, Vasanta Putluri, Abu Hena Mostafa Kamal, Nagireddy Putluri, Michael D Kornberg 

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, United States • Advanced Technology Core, Baylor College of Medicine, Houston, United States • Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

eLife Assessment

The results highlight an **important** physiological function of PGAM in the differentiation and suppressive activity of Treg cells by regulating serine synthesis. This role is proposed to intersect with glycolysis and one-carbon metabolism. Although the study's conclusion is supported by **solid** evidence from in-vitro cellular and in-vivo mouse models, there are some weaknesses and the reviewers suggested ways to improve the manuscript.

<https://doi.org/10.7554/eLife.104423.1.sa2>

Abstract

The differentiation and suppressive functions of regulatory CD4 T cells (Tregs) are supported by a broad array of metabolic changes, providing potential therapeutic targets for immune modulation. In this study, we focused on the regulatory role of glycolytic enzymes in Tregs and identified phosphoglycerate mutase (PGAM) as being differentially overexpressed in Tregs and associated with a highly suppressive phenotype. Pharmacologic or genetic inhibition of PGAM reduced Treg differentiation and suppressive function while reciprocally inducing markers of a pro-inflammatory, T helper 17 (Th17)-like state. The regulatory role of PGAM was dependent on the contribution of 3-phosphoglycerate (3PG), the PGAM substrate, to de novo serine synthesis. Blocking de novo serine synthesis from 3PG reversed the effect of PGAM inhibition on Treg polarization, while exogenous serine directly inhibited Treg polarization. Additionally, altering serine levels *in vivo* with a serine/glycine-free diet increased peripheral Tregs and attenuated autoimmunity in a murine model of multiple sclerosis. Mechanistically, we found that serine limits Treg polarization by contributing to one-carbon metabolism and methylation of Treg-associated genes. Inhibiting one-carbon metabolism increased Treg polarization and suppressive function both *in vitro* and *in vivo* in a murine model of autoimmune colitis. Our study identifies a novel physiologic role for PGAM and highlights the metabolic interconnectivity between glycolysis, serine synthesis,

one-carbon metabolism, and epigenetic regulation of Treg differentiation and suppressive function.

Introduction

Upon activation, immune cells undergo drastic metabolic changes that support their differentiation and effector functions. The regulation of immune responses by metabolic pathways, termed “immunometabolism”, has become a major focus of research with a goal of identifying pathways that can be targeted in conditions ranging from autoimmune and infectious diseases to cancer¹.

T lymphocytes in particular have emerged as a central focus of immunometabolic research with far reaching implications in human disease^{2–7}. Among the metabolic adaptations associated with T cell activation, glycolytic reprogramming plays a prominent role. Increased glucose uptake and augmented glycolysis are critical for the differentiation and effector functions of inflammatory T cell subsets, including effector CD8 cells and T-helper (Th) 1 and Th17 CD4 cells^{8–15}. In contrast, regulatory T cells (Tregs), which serve as the brakes of the immune response by promoting tolerance and suppressing inflammation, have a distinct glycolytic profile^{16,17}. Prior work has shown that initial engagement of glycolysis supports proliferation and migration of Tregs, whereas downregulation of glycolysis and greater engagement of fatty acid oxidation are required for expression of the Treg-specific transcription factor FOXP3 and Treg suppressive functions^{18–25}. In this regard, forced engagement of glycolysis was found to decrease FOXP3 expression²⁶ while inhibition of glycolysis favored Treg differentiation and suppressive functions^{15,25,27–29}. The relationship between glycolysis and Treg function is not straightforward, however. For instance, in human Tregs induced following weak stimulation of the T cell receptor (TCR), glycolysis supported Treg suppressive function by regulating DNA-binding activity of the glycolytic enzyme enolase-1 (ENO1)³⁰. Such findings suggest the possibility of a more nuanced role for glycolysis in Tregs, with individual glycolytic enzymes serving unique and perhaps disparate functions.

Here, we report that the glycolytic enzyme phosphoglycerate mutase (PGAM), which converts 3-phosphoglycerate (3PG) to 2-phosphoglycerate (2PG), is physiologically upregulated in Tregs and its enzymatic activity supports FOXP3 expression and Treg suppressive function. Pharmacologic or genetic inhibition of PGAM inhibited Treg differentiation and shifted CD4 T cells toward a pro-inflammatory, Th17-like state. Mechanistically, we found that PGAM regulates Treg differentiation by controlling flux through the de novo serine synthesis pathway. The PGAM substrate 3PG is also utilized for serine synthesis, and decreased PGAM enzyme activity led to increased serine synthesis through accumulation of 3PG. Both newly synthesized and imported extracellular serine inhibited Treg differentiation by contributing to one-carbon metabolism and promoting the methylation, and therefore silencing, of genes associated with Treg function. Manipulation of serine availability and the methylation cycle increased peripheral Tregs and attenuated disease in mouse models of multiple sclerosis and autoimmune colitis. Our finding that PGAM, a key glycolytic enzyme, physiologically supports Treg differentiation further challenges the notion that glycolysis plays a singular, inhibitory role in Tregs and suggests that individual glycolytic enzymes can serve as nodes for the fine-tuning of immune responses. Furthermore, our work identifies novel metabolic targets for the therapeutic manipulation of Treg function in human disease.

Results

PGAM regulates Treg differentiation and suppressive function

In order to identify the glycolytic enzymes that play the largest role in Treg differentiation, we analyzed multiple publicly available transcriptomic and proteomic datasets. We first investigated an RNA sequencing (RNA-seq) dataset that compared human naïve CD4 cells cultured under either Th0 or Treg polarizing conditions ³¹. After library normalization, we examined genes included in the “Glycolysis and Gluconeogenesis” gene ontology (GO) term and found that PGAM1 was the most differentially expressed glycolytic gene, with upregulation in *in vitro*-induced Tregs (iTregs) compared to conventional Th0 cells (**Figure 1A**). To determine whether PGAM expression is similarly upregulated in ex vivo-derived Tregs, we examined a single cell RNA-seq (scRNA-seq) dataset of peripheral blood mononuclear cells (PBMCs) from human healthy controls ³² and compared glycolytic gene expression between Tregs and total CD4 cells. After removing glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for scaling purposes, we found that PGAM1 was similarly upregulated in Tregs (**Figure 1B**). A proteomics dataset from human healthy donor PBMCs ³³ demonstrated significantly upregulated protein levels of PGAM1 and PGAM2 in Tregs compared to total CD4 cells (**Figure 1C**), confirming findings from the mRNA level.

The differential upregulation of PGAM in Tregs suggested that it might play a physiologic regulatory role in these cells. We therefore wondered whether PGAM inhibition impacts Treg differentiation. To answer this question, we used epigallocatechin gallate (EGCG), a known inhibitor of PGAM ³⁴. We cultured naïve murine CD4 cells under Treg polarizing conditions with either vehicle or EGCG and assessed Treg differentiation by quantifying the percentage of CD25⁺FOXP3⁺ cells by flow cytometry after 96 hours. Treatment with EGCG significantly reduced Treg differentiation (**Figure 1D**) without affecting proliferation or cell viability (Figure S1). To validate the effects of pharmacologic inhibition with genetic knockdown, we utilized antisense oligonucleotides (ASOs) targeting PGAM to reduce gene expression. Compared to scrambled control ASOs, we found that ASOs targeting PGAM reduced PGAM1 protein levels (Figure S2A) and significantly reduced Treg differentiation assessed by flow cytometry (**Figure 1E**). Because glycolysis is crucial for cell health, we wanted to know if PGAM knockdown was affecting survival and/or proliferation. We found that PGAM ASOs did not affect cell survival and led to a minor increase in cell proliferation (Figures S2B and S2C).

To gain further insights into the effects of PGAM knockdown on Treg differentiation, we performed RNA-seq transcriptional profiling from naïve murine CD4 cells cultured under Treg polarizing conditions with either scrambled or PGAM-specific ASOs. PCA analysis showed that PGAM ASOs led to major transcriptional changes (**Figure 1F**), with major effects on MYC targets and mTORC1 signaling (**Figure 1G**), among other changes. We then performed differential expression analysis on a subset of genes important in the Treg-Th17 axis and found that cells treated with PGAM ASOs had significantly higher expression of pro-inflammatory genes such as IL-17, IL-22, and IL-9, while significantly lower expression of genes involved in Treg differentiation such as FOXP3 and IZKF3 (**Figure 1H**). A complete list of differentially expressed genes can be found in Table S1.

Given the observed changes in transcriptional profile and differentiation markers, we next asked whether PGAM knockdown leads to functional changes in Treg suppressive activity. Compared to treatment with scrambled ASOs, PGAM ASO-treated Tregs were less effective at suppressing effector T (Teff) cell proliferation, indicating diminished suppressive function (**Figure 1I**). Consistent with this finding, analysis of a published scRNAseq dataset of tumor-infiltrating Tregs showed that PGAM1 is overexpressed relative to other glycolytic enzymes in the OX40^{hi}GITR^{hi} subset (**Figure 1J**), which was the most highly suppressive of the 10 Treg subsets identified ³⁵.

Taken together, these findings demonstrate a critical role for PGAM in supporting Treg differentiation and suppressive function, *in vitro* as well as in healthy and diseased human states. The positive regulatory role of PGAM in Tregs was intriguing, since glycolysis has generally been




Figure 1.

PGAM regulates Treg differentiation and suppressive function.

(A – C) Analysis of publicly available transcriptomics and proteomics data reveals upregulation of PGAM expression in human iTregs and ex vivo Tregs. (A) Publicly available RNAseq data from human naïve CD4 cells cultured under either Th0 or Treg polarizing conditions for 72 hours (Ubaid Ullah et al., 2018) was analyzed, and genes belonging to the Gene Ontology (GO) term “Glycolysis and Gluconeogenesis” were plotted. (B) Differential expression of “Glycolysis and Gluconeogenesis” GO genes in ex vivo Tregs vs. total CD4 cells derived from healthy donor PBMCs (Schafflick et al., 2020). GAPDH was removed for scaling purposes. (C) Differential expression of cytosolic glycolytic enzymes in ex vivo Tregs vs. conventional CD4 T cells derived from healthy donor PBMCs, analyzed from publicly available proteomics data (Procaccini et al., 2016). (D) Naïve murine CD4 cells were cultured under Treg polarizing conditions for 4 days and treated with either EGCG (20 μ M) or vehicle on day 1. Treg polarization based on CD25 and FOXP3 expression was analyzed by flow cytometry. Data represent mean $\pm$ SEM from 4 independent experiments, with 3-4 biological replicates per experiment. (E) Naïve murine CD4 cells were treated with either scrambled or PGAM-specific antisense oligonucleotides (ASOs) and cultured under Treg polarizing conditions for 72 hours. CD25 and FOXP3 expression were analyzed by flow cytometry. Data represent mean $\pm$ SEM from 5 independent experiments, with 3-4 biological replicates per experiment. (F – H) Naïve murine CD4 cells were cultured with either scrambled or anti-PGAM ASOs for 72 hours under Treg polarizing conditions. RNA was isolated for RNAseq, followed by library size normalization and differential expression analysis. Shown are (F) PCA plot for scrambled and anti-PGAM ASOtreated cells, (G) Gene Set Enrichment Analysis (GSEA) using MSigDB Hallmark gene sets and (H) volcano plot of genes associated with T cell function. Data from 3 biological replicates. (I) Naïve murine CD4 cells were cultured under Treg polarizing conditions with either scrambled or anti-PGAM ASOs for 72 hours. To assess Treg suppressive function, the polarized Tregs were cultured with naïve CD4 cells stimulated with CD3/CD28 stimulating antibodies for an additional 72 hours at the indicated ratios. Cell proliferation was measured by dilution of a cell proliferation dye. Data represent mean $\pm$ SEM from 4 biological replicates. (J) Analysis of a published scRNAseq dataset of tumor-infiltrating Tregs (Dykema et al., 2023) shows that *PGAM1* is overexpressed in the most highly suppressive subpopulation, out of proportion to proximal rate-limiting glycolytic enzymes. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.0001$ by Mann-Whitney U Test (D, E) or two-way ANOVA with multiple comparisons testing (I). P-values in (A), (B), and (F – H) were derived from Wald’s test after False Discovery Rate correction and median-of-ratios normalization via DESeq2.

associated with decreased Treg function. Our own prior work found that inhibition of GAPDH, which catalyzes a reaction only two steps upstream from PGAM in glycolysis, augments Treg differentiation²⁸—a finding we replicated here with the GAPDH inhibitor koniginic acid (Figure S3). The discordant roles of GAPDH and PGAM led us to focus on the metabolites whose concentrations are immediately impacted by PGAM enzymatic activity.

PGAM regulation of Treg differentiation is mediated by 3PG and de novo serine synthesis

PGAM metabolizes the glycolytic intermediate 3PG into 2PG^{36,37}. In addition to its role in glycolysis, 3PG is the starting substrate for the de novo serine synthesis pathway^{38,39}. Given previous work implicating various roles for serine in T cells^{40–42}, we hypothesized that PGAM enzymatic activity regulates Treg differentiation and function by controlling levels of 3PG with downstream effects on serine synthesis (Figure 2A). To test this hypothesis, we first cultured naïve murine CD4 cells under Treg-polarizing conditions with either vehicle or the PGAM inhibitor EGCG and measured intracellular serine levels by mass spectrometry. As anticipated, PGAM inhibition with EGCG increased intracellular levels of serine in Tregs (Figure 2B). We next asked whether glucose-derived de novo serine synthesis is physiologically regulated during Treg differentiation, focusing on the reciprocal Treg-Th17 axis. We differentiated naïve murine CD4 cells into either Tregs or Th17 cells for 72 hours. After 6-hour glucose starvation, the cells were incubated with uniformly 13-carbon labeled glucose (U¹³C-glucose) for an additional 6 hours. Using mass spectrometry, we found that ¹³C-labeling of serine was significantly higher in Th17 cells compared to Tregs (Figure 2C), indicating that flux through de novo serine synthesis is physiologically downregulated in Tregs compared to Th17 cells.

If the role of PGAM in Treg differentiation depends on de novo serine synthesis, then the effects of PGAM inhibition should be rescued by simultaneously blocking the serine synthesis pathway. To this end, we cultured naïve murine CD4 cells under Treg-polarizing conditions and treated them with the PGAM inhibitor EGCG ± NCT-503, an inhibitor of phosphoglycerate dehydrogenase (PHGDH, the ratelimiting enzyme of serine synthesis from 3PG)^{43,44}. As before, PGAM inhibition with EGCG inhibited Treg differentiation as assessed by FOXP3 expression, but this was reversed by PHGDH inhibition with NCT-503 (Figure 2D). Similarly, if PGAM regulates Tregs by controlling concentrations of 3PG (the substrate for serine synthesis), then direct supplementation of 3PG should replicate the effects of PGAM inhibition. To test this, 3PG was delivered to naïve murine CD4 cells via electroporation followed by Treg polarization. As expected, 3PG supplementation decreased FOXP3 expression, which was rescued by PHGDH inhibition with NCT-503 (Figure 2E). To further validate the role of de novo serine synthesis in Tregs, we used PHGDH-targeted ASOs and found that genetic knockdown of PHGDH led to augmented Treg differentiation as assessed by FOXP3 expression (Figure 2F).

The above findings demonstrate that PGAM regulates Treg differentiation by controlling flux through the serine synthesis pathway. Because serine can be derived from both de novo intracellular synthesis and extracellular sources, we next asked whether extracellular serine also affects Treg differentiation. We cultured naïve murine CD4 cells under Treg-polarizing conditions in either serine/glycine-free media or control (serine/glycine-containing) media. Deprivation of both serine and glycine is required to evaluate the role of extracellular serine, as glycine can be converted to serine via the enzyme serine hydroxymethyltransferase (SHMT)³⁹. The presence of extracellular serine diminished Treg differentiation (Figure 2G), indicating that both synthesized and exogenous serine impact Treg generation.

Synthesized and dietary serine regulate Treg function in vivo

After finding that serine derived from both extracellular sources and de novo synthesis inhibits Treg polarization *in vitro*, we investigated the effect on Tregs of altering serine availability *in vivo*. We first examined the impact of dietary serine restriction by maintaining mice immediately post-




Figure 2.

PGAM regulates Treg differentiation through control of de novo serine synthesis.

(A) Schematic diagram of the intersection of glycolysis and the de novo serine synthesis pathway via the PGAM substrate 3PG. Pharmacologic inhibitors are shown in red boxes. (B) Naïve murine CD4 cells were cultured under Treg polarizing conditions for 4 days and treated with vehicle or EGCG (20 μ M) on day 1. Cells were then lysed and metabolites were extracted and analyzed via LC-MS. Data from 4 biological replicates. (C) The rate of glucose-derived serine synthesis from polarized murine Tregs or Th17 cells was measured by adding $U^{13}C$ -glucose to the culture media for 6 hours and quantifying the percentage of labeled/unlabeled serine via LC-MS. The mass isotopomer distribution (MID) of $U^{13}C$ -glucose-derived serine and percent contribution to the total serine pool is shown. Data represent mean $\pm$ SEM from 3 biological replicates. (D) Naïve murine CD4 cells were cultured under Treg polarizing conditions for 4 days. On day 1, the cells were treated vehicle or the indicated combinations of the PGAM inhibitor EGCG (10 μ M) and the PHGDH inhibitor NCT-503 (10 μ M). Treg polarization was assayed by flow cytometry. Data represent mean $\pm$ SEM from 5 independent experiments. (E) Naïve murine CD4 cells were polarized under Treg conditions for 4 days. On day 1 of polarization, cells were either sham-electroporated or supplemented with 3PG (1.5 mM) by electroporation and treated with vehicle or the PHGDH inhibitor NCT-503 (10 μ M). Analysis was performed by flow cytometry. Data represent mean $\pm$ SEM from 5 independent experiments. (F) Naïve CD4 cells were cultured under Treg polarizing conditions with either scrambled or anti-PHGDH ASOs, and Treg generation was analyzed by flow cytometry. Data represent mean $\pm$ SEM from 4 independent experiments. (G) Naïve murine CD4 cells were cultured under Treg polarizing conditions for 4 days with either serine/glycine-free media or media containing 4 mM serine, followed by flow cytometric analysis. Data represent mean $\pm$ SEM from 4 independent experiments. * P < 0.05, ** P < 0.01 by Mann-Whitney U test (F, G), Kruskal Wallis test with multiple hypothesis correction (D, E), or student's t test with multiple hypothesis correction (C). Each independent experiment shown in D – G included 3-4 biological replicates. Panel A was created using BioRender.com.

weaning on either a serine/glycine-free diet or isocaloric control diet. After 8 weeks, we measured Treg abundance in peripheral blood by flow cytometry. Mice fed a serine/glycine-free diet had significantly higher proportions of Tregs in peripheral blood (**Figure 3A**). To determine whether this effect on Tregs translates to protection in a murine model of autoimmunity, we used the myelin oligodendrocyte glycoprotein (MOG)^{35–55} experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (MS). Mice were transitioned to a serine/glycine-free or isocaloric control diet beginning one week prior to immunization with MOG^{35–55}, and disease severity was monitored by a blinded scorer. A serine/glycine-free diet significantly attenuated disease severity, delaying the onset of neurologic deficits and reducing peak clinical scores (**Figures 3B–D**).

We next asked whether de novo serine synthesis is altered in human Tregs in disease. Using publicly available RNA-seq and scRNA-seq data, we estimated the rate of de novo serine synthesis using single cell flux estimation analysis (SCFEA)⁴⁵, which constructs a global set of metabolic reactions as a factor map and uses multi-layer neural networks to model reaction rates from mRNA levels of metabolic enzymes. We applied SCFEA to human Th0 and iTreg cells differentiated from naïve CD4 cells *in vitro*³¹ and found that serine synthesis was downregulated in iTregs (**Figure 3E**). Autoimmunity occurs when Tregs fail to adequately regulate the immune response, so we wondered whether the predicted rate of de novo serine synthesis would be altered in Tregs derived from patients with autoimmune disease. Using scRNA-seq data derived from Tregs isolated from the cerebrospinal fluid (CSF) of patients with treatment-naïve relapsing MS and controls³², we found the predicted rate of serine synthesis was significantly higher in Tregs from MS patients (**Figure 3F**). Conversely, while autoimmunity results from inadequate Treg suppressive function, Tregs in the tumor microenvironment have pathologically high suppressive function. We examined scRNA-seq data from Tregs derived from healthy prostate and prostate cancer⁴⁶ from the IMMUCan database⁴⁷ and found that prostate tumor-infiltrating Tregs had significantly lower predicted serine synthesis than Tregs from healthy prostate (**Figure 3G**). Consistent with our earlier findings that serine synthesis inhibits Treg function, these analyses suggest that serine synthesis within Tregs is higher in autoimmunity and lower in the tumor microenvironment, thereby negatively correlating with expected Treg suppressive function in human disease.

Serine inhibits Treg generation by contributing to one-carbon metabolism and DNA methylation

We next examined the mechanistic links between serine metabolism and Treg function. Serine can serve as a one-carbon donor by entering the one-carbon metabolism cycle, which depends on conversion into glycine by the enzyme SHMT1/2⁴⁸ (**Figure 4A**). To determine whether the effects of serine on Treg differentiation depend on contributions to one-carbon metabolism, we cultured naïve murine CD4 cells under Treg polarizing conditions with either vehicle or the SHMT1/2 inhibitor SHIN1^{49,50}. Inhibiting SHMT1/2 increased Treg polarization (**Figure 4B**) and mitigated the inhibitory effect of extracellular serine on Tregs (**Figure 4C**). Because methionine can compensate as a one-carbon donor, other groups have found that the contribution of serine to one-carbon metabolism is greater in the absence of methionine⁵¹. To further the idea that serine inhibits Treg polarization by contributing to one-carbon metabolism, we cultured naïve murine CD4 cells under Treg polarizing conditions in methionine-free media supplemented with either methionine or additional serine. Although methionine supplementation had little effect, excess extracellular serine was highly potent in inhibiting Treg polarization in the absence of methionine (**Figure 4D**). These studies suggest that the regulatory role of serine in Tregs is mediated at least in part through one-carbon metabolism.

A crucial role of one-carbon metabolism is to provide methyl groups for methylation reactions, and DNA methylation represents a key epigenetic mechanism used to silence gene transcription⁵². We therefore asked whether serine entry into one-carbon metabolism




Figure 3.

Serine synthesis and dietary availability regulate Tregs in vivo and in disease states.

(A) C57BL/6 mice were fed either serine/glycine-free diet or control diet for 8 weeks, beginning immediately post-weaning. Peripheral Tregs from blood were quantified by flow cytometry as the percentage of CD45⁺ cells expressing FOXP3. Data represent mean $\pm$ SEM from 4-5 mice per group. (B – D) Mice were fed either serine/glycine-free diet or control diet for 7 days and then subjected to MOG₃₅₋₅₅ EAE. Clinical scoring was performed by a blinded observer. Data represent mean $\pm$ SEM from 8 mice per group. Shown are (B) clinical scores over the course of the experiment, (C) day of neurologic symptom onset, and (D) peak clinical scores. (E – G) Publicly available RNAseq data from three different datasets was analyzed using SCFEA to model serine synthesis rates from mRNA levels of metabolic enzymes. (E) SCFEA from human naïve CD4 cells cultured under either Th0 or Treg polarizing conditions for 72 hours (Ubaid Ullah et al., 2018) predicts decreased serine synthesis in iTregs. (F) Predicted serine synthesis is increased in Tregs derived from cerebrospinal fluid of patients with treatment-naïve relapsing MS compared to controls (Schafflick et al., 2020). (G) Predicted serine synthesis is decreased in Tregs derived from prostate cancer versus control prostate (Camps et al., 2023). * $P < 0.05$, ** $P < 0.01$, **** $P < 0.00001$ by student's t-test (A, E, F, G), Mann-Whitney U test (C, D), and two-way ANOVA with repeated measures (B).




Figure 4.

Serine inhibits Treg polarization by contributing to one-carbon metabolism and methylation of Treg-associated genes.

(A) Schematic diagram of serine entry into one-carbon metabolism and the methyl donor cycle. Pharmacologic inhibitors are shown in red boxes. **(B)** Naïve murine CD4 cells were cultured under Treg polarizing conditions for 72 hours with either vehicle or SHIN1 (SHMT1/2 inhibitor, 1 μ M) added at day 0 of culture. Treg polarization was assayed by flow cytometry. Data represent mean $\pm$ SEM from 4 independent experiments, with 3-4 biological replicates per experiment. **(C)** Naïve murine CD4 cells were cultured in serine/glycine-free media, media containing 4 mM serine, or media with serine plus SHIN1 (1 μ M). Treg polarization was assayed by flow cytometry. Data represent mean $\pm$ SEM from 3-4 biological replicates per condition. **(D)** Naïve murine CD4 cells were cultured in methionine-free media supplemented with vehicle, 1 mM methionine, or 4 mM serine, and FOXP3 expression was assayed by flow cytometry. Data represent mean $\pm$ SEM from 3 biological replicates. **(E)** Naïve murine CD4 cells were cultured in serine/glycine-free media for 48 hours under Treg polarizing conditions and then for 12 hours with either unlabeled serine or U¹³C-serine. The mass isotopomer ratio of carbon-labeled methylcytosine (m+1) / unlabeled methylcytosine is shown. Data represent mean $\pm$ SEM from 3 biological replicates. **(F)** Naïve CD4 cells were cultured under Treg polarizing conditions with either serine/glycine-free media or 4 mM serine. Methylation at the FOXP3 TSDR was assayed by pyrosequencing. The composite methylation was calculated as the percent methylation for each of the 4 CpG sites measured in the assay normalized to the serine/glycine-free condition. Data derived from 3 biological replicates per condition. **(G)** Naïve CD4 cells were cultured under Treg polarizing conditions with either scrambled or anti-PGAM ASOs. Methylation at the FOXP3 TSDR was assayed by pyrosequencing. The composite methylation was calculated as the percent methylation at each of the 4 CpG sites measured in the assay normalized to scrambled control. Data derived from 3 biological replicates per condition. **(H)** Naïve murine CD4 cells were cultured in serine/glycine-free media, media containing 4 mM serine, or media with serine plus SHIN1 (1 μ M). Bisulfite-treated DNA was sequenced using a Treg-specific next generation sequencing panel, and percent methylation of key sites was calculated. Data derived from 3 biological replicates per condition. **(I)** Naïve CD4 cells were cultured under Treg polarizing conditions with either vehicle or 3-Deazaadenosine (3DZA, AHCY inhibitor, 5 μ M). Treg polarization was assayed by flow cytometry. Data represent mean $\pm$ SEM from 4 independent experiments, with 3-4 biological replicates per experiment. **(J)** Naïve CD4 cells were polarized to Tregs with either vehicle or 3DZA and then cultured with CD4 cells stimulated with CD3/CD28 to evaluate Treg suppressive function. CD4 cell proliferation was measured by flow cytometry. Data represent mean $\pm$ SEM from 3 biological replicates. **(K)** Naïve CD4 cells were cultured under Treg polarizing conditions with either vehicle or 3DZA, and 10⁶ cells were then transferred into RAG^{-/-} mouse recipients along with 10⁷ activated CD4 cells. Mice were weighed at the specified times and weights are shown relative to the weight at the day of injection. Data represent mean $\pm$ SEM from 5 mice per group. **P* < 0.05, ***P* < 0.01 by Mann-Whitney U test (B, F, G, I), one-way ANOVA with Tukey's multiple comparisons testing (C, D), two-way ANOVA with Dunnett's multiple comparison testing (H), student's t-test of average final weight (K), or student's t test (J). Panel A was created using BioRender.com.

contributes to DNA methylation in Tregs, so we conducted a carbon tracing experiment in which Tregs were cultured in media containing uniformly 13-carbon labeled serine (U¹³C-serine) for 12 hours before DNA was isolated and analyzed by mass spectrometry. We found that serine directly contributed to cytosine methylation, as measured by carbon labeling of methylcytosine (**Figure 4E**). Demethylation of the Treg-specific demethylated region (TSDR) in Tregs is a critical step for generation of stable, bona fide Tregs, and methylation in this region is associated with transient or unstable expression of FOXP3 and suppressive activity⁵³. We therefore investigated the effects of extracellular serine and PGAM knockdown on methylation of the TSDR via pyrosequencing. In a first set of experiments, naïve murine CD4 cells were cultured under Treg polarizing conditions in either serine/glycine-free media or media containing serine. The presence of extracellular serine increased TSDR methylation (**Figure 4F**). Genetic knockdown of PGAM using ASOs similarly increased TSDR methylation (**Figure 4G**). Taken together, these findings demonstrate that both extracellular serine and PGAM-regulated serine synthesis increase the methylation, and therefore silencing, of Treg-associated genes.

Given the promising results seen with pyrosequencing, we next used a next generation sequencing panel to identify CpG sites in Treg-specific genes whose methylation is regulated by serine (**Figure 4H**). Methylation of *IKZF2* (Helios) was significantly increased with the addition of extracellular serine, but this was reversed by blocking serine entry into one-carbon metabolism with the SHMT inhibitor SHIN1. In the 5' upstream region of the *FOXP3* gene, one CpG site showed significantly higher methylation in the presence of serine, and this effect was reversed by SHIN1. A complete list of CpG methylation levels can be found in Table S2.

To definitively link methylation to Treg differentiation and suppressive function, we blocked methylation in Tregs with 3-Deazaadenosine (3DZA), an inhibitor of S-adenosylhomocysteine (SAH) hydrolase. SAH hydrolase degrades SAH and prevents recycling of the methyl donor S-adenosylmethionine (SAM)⁵⁴. In naïve murine CD4 cells cultured under Treg polarizing conditions, 3DZA increased Treg differentiation (**Figure 4I**) without affecting cell viability (Figure S4). Treatment with 3DZA similarly augmented suppressive function in cultured murine Tregs (**Figure 4J**). To determine the *in vivo* relevance of these findings, we used an adoptive transfer autoimmune colitis mouse model. Conventional murine CD4 cells were activated *ex vivo* and injected into RAG^{-/-} mice to induce colitis, along with simultaneous injection of Tregs that had been treated during differentiation with either vehicle or 3DZA. Mice injected with Tregs polarized in the presence of 3DZA had less severe disease as measured by weight loss and macroscopic examination of the colon (**Figures 4K** and S5), indicating greater Treg suppressive function. Altogether, these findings demonstrate that one-carbon metabolism and methylation impair Treg differentiation and suppressive function both *in vitro* and *in vivo*.

Discussion

In this study, we found that PGAM plays a key physiologic role in Treg differentiation and suppressive function through regulation of serine synthesis, which intersects with glycolysis immediately upstream of PGAM through the shared substrate 3PG. Analysis of published datasets revealed that PGAM expression is specifically increased within human Tregs at both transcriptional and protein levels, and further that PGAM expression is enriched in highly suppressive Treg phenotypes. Pharmacologic inhibition or genetic knockdown of PGAM reduced Treg polarization and suppressive function while promoting a proinflammatory gene signature. These effects were replicated by exogenous supplementation of 3PG and reversed by inhibition of serine synthesis. Single cell flux estimation analysis predicted increased serine synthesis in Tregs isolated from patients suffering from autoimmune disease and decreased serine flux in tumor-associated Tregs, underlining the clinical importance of this regulatory pathway. Consistent with a previous report⁴², we found that both synthesized and exogenously imported serine impact Treg function. Mechanistically, serine inhibited Treg polarization by increasing flux through one-

carbon metabolism with downstream effects on DNA methylation of Treg-related genes. Interfering with serine availability or methylation attenuated disease in *in vivo* models of autoimmunity.

The surprising role of PGAM in Treg differentiation has both physiologic and therapeutic implications. Although glycolysis has been shown to support initial proliferation and migration of Tregs^{21,30}, most prior work has suggested that glycolytic flux supports effector T cell functions with concomitant downregulation of Treg stability and suppressive activity^{29,55–57}. Indeed, previous studies have shown Tregs to depend on fatty acid oxidation and oxidative phosphorylation, largely independent of glycolysis^{17,58,59}. Our own prior work found that inhibition of GAPDH, an enzyme two catalytic reactions upstream of PGAM in glycolysis, enhances Treg differentiation²⁸, with similar findings observed following inhibition or knock-down of other proximal glycolytic enzymes^{15,22,27,60}. It is striking, therefore, that PGAM enzymatic activity has the opposite effect, supporting Treg differentiation and suppressive functions. Inhibition or knockdown of PGAM not only prevented Treg polarization but reciprocally enhanced markers of a pro-inflammatory, Th17-like phenotype, implicating PGAM as a physiologic regulator of the balance between pro- and anti-inflammatory lymphocyte responses via regulation of serine synthesis. These findings suggest that glycolytic regulation of immunity is more complex than previously appreciated, supporting a more granular view in which glycolytic enzymes can serve as independent regulatory nodes for the fine-tuning of immune responses.

From a therapeutic perspective, our findings identify novel targets for modulating Treg function in disease. Substantial prior work has shown that manipulation of glycolysis and other metabolic pathways has a therapeutic window for systemic administration despite the ubiquity of these pathways in cell biology⁶¹. Nonetheless, systemic administration may not be necessary for several key therapeutic applications, for instance optimization of chimeric antigen receptor (CAR)-T cell therapies^{62–64}. Differentiation of CAR-T cells into a Treg-like state correlates with failure of CAR-T therapy in B cell lymphoma⁶⁵, such that manipulation of PGAM and downstream serine metabolism and DNA methylation is a potential strategy for improving the anti-cancer fitness of CAR-T cells *ex vivo* prior to infusion. Conversely, CAR-Tregs are currently in clinical trials for a variety of autoimmune disorders^{66,67}, and there is widespread interest in treatments that improve the suppressive activity of Tregs.

Of note, a prior study reported that complete knockout of PGAM1 in T cells impaired differentiation and effector functions of pro-inflammatory T cell subsets with only mild impact on Treg generation⁶⁸. However, complete knockout of a glycolytic enzyme would be expected to abrogate glycolytic flux entirely, with wide-ranging effects (including decreased energy production) likely to mask the impact of physiologic or therapeutic modulation of enzyme function. As we showed here, partial knockdown or pharmacologic inhibition of PGAM1, which decrease but do not fully abrogate enzymatic activity, substantially reduced Treg differentiation while supporting pro-inflammatory activation. Additionally, other groups studying glycolysis in cancer used partial knockdowns to show that PGAM supports tumor proliferation by controlling flux through the *de novo* serine synthesis pathway⁶⁹.

Our investigation focused on the contribution of one-carbon metabolism to DNA methylation, which is particularly relevant in Tregs given the established regulatory role of methylation of Treg-specific genes, including the Treg Specific Demethylated Region (TSDR) of the FOXP3 gene locus^{70–73}. However, one-carbon metabolism contributes to many cellular processes, including purine synthesis, amino acid metabolism, and phospholipid synthesis, among others⁵², so it is likely that one-carbon metabolism inhibits Treg differentiation in a variety of ways. Although other groups have also identified the importance of one-carbon metabolism in Treg generation⁷⁴, we describe novel links between glycolysis, serine synthesis, and DNA methylation as a regulatory pathway of Treg differentiation.

In summary, we have found an unexpected role of PGAM that adds further nuance to the complex relationship between glycolysis and Treg function and further implicates serine and its contributions to onecarbon metabolism and DNA methylation as key regulators of Treg differentiation. In addition to yielding new biological insights into the metabolic regulation of lymphocyte fate and function, these findings point to new strategies for the therapeutic manipulation of Treg function.

Methods

Key resources table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-murine CD25, BV785	Biolegend	102051
Anti-murine FOXP3, APC	ThermoFisher	17-5773-80
Zombie NIR fixable viability	Biolegend	423106
PGAM1 Antibody [Alexa Fluor® 405]	Novus Biologicals	NBP1-49532AF405
CD3 Monoclonal Antibody (OKT3), Functional Grade, eBioscience™	Thermofisher	16-0037-81
CD28 Monoclonal Antibody (37.51), Functional Grade, eBioscience™	Thermofisher	16-0281-82
InVivoPlus anti-mouse IFN γ	BioXcell	BP0055
InVivoMAb anti-mouse IL-4	BioXcell	BE0045
Chemicals, peptides, and recombinant proteins		
SHIN1	MCE	HY-112066
NCT-503	Sigma	SML1659-5MG
EGCG	Millipore Sigma	E4143-50MG
3-DZA	Cayman	9000785
Heptelidic Acid	Cayman	14079
D-(-)-3-Phosphoglyceric Acid (Sodium Salt)	Cayman	20123
D-(+)-Glucose-13C6	Cayman	26707
L-Serine-13C3	Cayman	35126
Critical commercial assays		
Cell Proliferation Dye	eBioscience	65-0842-85
Deposited data		
RNA-sequencing data from scramble or anti-PGAM ASO	This paper	To be deposited upon publication
Experimental models: Organisms/strains		
C57BL/6J wild type mice	Jackson Laboratory	000664
B6.129S7- <i>Rag1^{tm1Mom}</i> /J (RAG knockout mice)	Jackson Laboratory	002216
Oligonucleotides		
Anti-sense PGAM1 oligonucleotides	Custom Order	Aum Biotech
Anti-sense PHGDH oligonucleotides	Custom Order	Aum Biotech
Other		
Animal-Free Recombinant Murine IL-2	AF-212-12	ThermoFisher
RECOMBINANT HUMAN TGF BETA 1	PHP143B	Biorad
Murine IL-6	216-16	Peprtech
Recombinant Mouse IL-23 (carrier-free)	589002	Biolegend
Murine IL-1beta	211-11B	Peprtech
MojoSort(TM) Mouse CD4 Naive T Cell Isolation Kit	480040	Biolegend

MojoSort(TM) Mouse CD4 T Cell Isolation Kit	480006	Biolegend
Serine/Glycine-free diet	1812281	Animal Specialty and Provisions
Control Diet	1817070-209	Animal Specialty and Provisions

Resource Availability

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael D. Kornberg (michael.kornberg@jhmi.edu).

Materials Availability

This study did not generate new unique reagents.

Data and Code Availability

All data supporting the findings of this study are presented and/or tabulated within the Article or Supplemental Information. All large-scale sequencing data will be deposited at GEO upon publication.

Experimental Model and Subject Details

Animals

Wild type C57BL/6J (stock # 000664) and B6.129S7-*Rag1*^{tm1Mom}/J RAG knockout mice (stock # 002216) were purchased from The Jackson Laboratory. All mice were housed in a dedicated Johns Hopkins mouse facility. All protocols were approved by the Johns Hopkins Institutional Animal Care and Use Committee.

Primary Cell Cultures

CD4+ T-Cell Isolation and Culture

T-cells were isolated by generating single-cell suspensions from the spleen and lymph nodes of 6–10-week-old C57BL/6 mice. Spleens were mechanically dissociated with the plunger of a syringe over a 100-μm cell strainer (BD Falcon), then were pelleted by centrifugation (1500 RPM for 5 min) and resuspended in fresh FACS buffer. Naive CD4+ cells were isolated by negative selection using the MojoSort CD4+ naïve T-cell isolation kit from Biolegend (Catalog 480040) according to the manufacturer's instructions. Plates were coated overnight at 4°C with plate-bound anti-mouse CD3 antibody (2 μg/mL). Prior to plating, cells were resuspended in complete 50% RPMI (RPMI plus 10%FBS, 1% Pen-strep, 1% glutamax, 0.1% 2-mercaptoethanol) and 50 % AIM-V media along with 2 ug/mL soluble anti-mouse CD28 antibody. Experiments involving serine/glycine-free media or methionine-free media were done with 100%complete RPMI lacking the corresponding amino acid(s). Treg polarizing conditions included 10 ng/ mL murine IL-2 and 1 ng/mL human TGF-β along with 5 ug/mL anti-mouse IFNγ and 5 ug/mL anti-mouse IL-4. Experiments with Treg polarization for Treg suppression assays were performed with 15 ng/mL human TGF-β and 10 ng/mL retinoic acid.

Method Details

Drug and ASO Treatments

For drug treatments, cells were treated with the indicated drug at the indicated concentration. EGCG was dissolved in EtOH, while NCT-503 and SHIN1 were dissolved in DMSO. Antisense oligonucleotides were dissolved in PBS and added at 10 μ M directly to the cell culture media starting at day 0.

Electroporation

For electroporation with 3-phosphoglycerate (3PG), naïve CD4 cells were cultured for 24 hours under Treg polarizing conditions, and pre-treated with NCT-503 or vehicle for 4 hours prior to electroporation as indicated. Cells were then harvested, centrifuged, and resuspended in BTX high performance electroporation solution (45-0803) with either 1.5 mM 3-PG or PBS as indicated. Electroporation was performed at 500 V for 3 ms with 1 pulse/square in a 4 mM BTX electroporation cuvette. Cells were then immediately added to complete RPMI media that contained 1.5 mM 3-PG or PBS and rested for 2-4 hours. Cells were then centrifuged and resuspended with the media they were in prior to electroporation.

Flow Cytometry

Cells were stained with zombie NIR (1:1000) for 10 minutes and then washed with Flow Wash Buffer (PBS+ 2% fetal bovine serum + 2 mM EDTA). They were then stained with anti-CD25 (BV785) for 30 minutes. Cells were then washed with Flow Wash buffer two times and fixed with FoxP3 fixation/permeabilization buffer following the manufacturer recommended protocol. Intracellular staining was performed with conjugated antibodies (1:200) against the specified proteins in permeabilization buffer for 1 h, washed twice, and then analyzed cells with a Cytex Aurora Flow cytometer. Data analysis was performed with FlowJo software.

Treg Suppression Assay

To generate Tregs for the Treg suppression assay, naïve CD4 T cells were cultured for 4 days under Treg polarizing conditions. Then, total CD4⁺ T cells were isolated from murine spleens using Biolegend Mojo CD4 T cell isolation kit (480006) and labelled with Cell Proliferation Dye (eBioscience, #65-0842-85) by incubating in a 1:2000 dilution (PBS) for 10 minutes, washing 1X with PBS, and then washing 2X with complete RPMI. CD4⁺ T cells were cultured as described above (3 μ g/mL anti-CD3, 3 μ g/mL anti-CD28, 10 ng/mL recombinant murine IL-2) with varying ratios of Treg:Teffector cells. Divisions were counted by measuring cell proliferation dye dilutions with flow cytometry after a 3-day culture.

Mouse Peripheral Blood Samples

Mice were fed either serine/glycine-free diet or control diet (Animal Specialty and Provisions, 1812281 and 1817070-209) for 8 weeks immediately post-weaning and peripheral blood samples were obtained via cheek bleed into a microfuge tube coated with heparin/EDTA. RBCs were lysed with RBC lysis buffer for 7 minutes and then the reaction was stopped with HBSS (including Calcium and Magnesium). Cells were then stained with zombie NIR (1:1000) and anti-CD16/32 (1:200) for 10 minutes then stained with anti-CD45, anti-CD11b and anti-CD4 for 30 minutes. Staining then proceeded as described in the flow cytometry section.

Mass Spectrometry

Sample preparation for steady-state measurement of serine involved culturing CD4 T cells for 72 hours under Treg polarizing conditions, followed by treatment with the indicated drugs for 24 hours. The cells were collected, washed with PBS, and equal numbers of cells per condition were pelleted and flash-frozen. The frozen cell pellets were shipped to the Metabolomics Core at Baylor

College of Medicine, Houston, TX. The cells were then resuspended in a 500- μ l mixture of 1:1 water/methanol, sonicated for one minute (two 30-second pulses), and mixed with 450 μ l of ice-cold chloroform. The resulting homogenate was combined with 150 μ l of ice-cold water, vortexed for five minutes, incubated at -20°C for 30 minutes, and centrifuged at 4°C for ten minutes to partition the aqueous and organic layers. The combined layers were dried at 37°C for 45 minutes in a SpeedVac system (Genevac EZ Solvent Evaporator, SP Industries, Inc.). The extract was reconstituted in a 500- μ l solution of methanol/water (1:1) and filtered through a 3-kDa molecular filter (Amicon® Ultra Centrifugal Filter, 3 kDa MWCO, Millipore Sigma) at 4°C for 90 minutes to remove proteins. The filtrate was dried at 37°C for 90 minutes in a SpeedVac and stored at -80°C until mass spectrometric analysis. Prior to mass spectrometric analysis, the dried extract was resuspended in methanol/water (1:1).

For amino acid flux analysis, CD4 T cells were cultured for 6 hours in glucose-free media, then 12 mM U13C-glucose was added for 6 hours. The cells were resuspended in a 500- μ l mixture of 1:1 water/methanol, sonicated for one minute (two 30-second pulses), centrifuged at 4°C for ten minutes, and filtered through a 3-kDa molecular filter (Amicon® Ultra Centrifugal Filter, 3 kDa MWCO, Millipore Sigma) at 4°C for 90 minutes to remove proteins. The samples were dried at 37°C for 45 minutes in a SpeedVac system (Genevac EZ Solvent Evaporator, SP Industries, Inc.). Prior to mass spectrometry analysis, the dried extract was resuspended in methanol/water (1:1).

CD4 T cells were cultured under Treg polarizing conditions in serine-free media to measure methylcytosine flux, followed by the addition of either normal serine or 13C3-serine for 12 hours. The cells were harvested, the pellets were washed, and DNA was isolated using the Qiagen DNeasy Blood & Tissue Kit. DNA was quantified with a Nanodrop, and all samples were normalized based on total DNA content before mass spectrometry analysis. The details of the DNA hydrolysis methods were previously described (PMID: 27158554). DNA was denatured at 100°C for 3 minutes, incubated with ammonium acetate and nuclease P1, then mixed and incubated with venom phosphodiesterase I, followed by incubation with alkaline phosphatase. The details of the liquid chromatography-mass spectrometry (LC-MS) methods were also described earlier (PMID: 27158554).

For the LC-MS analysis method for serine steady state and tracing study of serine and methylcytosine, chromatographic separation of extracted metabolites, including serine, was performed through Hydrophilic Interaction Chromatography (HILIC) using an XBridge Amide column (3.5 μ m, 4.6 x 100 mm, Waters, Milford, MA) in ESI-positive ionization mode. Solvent A (0.1% formic acid in water) and Solvent B (0.1% formic acid in acetonitrile) were used for chromatographic separation (Ref). The data were acquired via multiple reaction monitoring (MRM) using a 6495 Triple Quadrupole mass spectrometer coupled to an HPLC system (Agilent Technologies, Santa Clara, CA) through Agilent Mass Hunter Data Acquisition Software (ver. 10.1) (PMID: 31360899, PMID: 30642841). The acquired mass spectra were analyzed and integrated into each targeted compound peak using Agilent Mass Hunter Quantitative Analysis Software. For serine measurement, peak areas were normalized with a spiked internal standard. Differential metabolites were determined using p-values from t-tests following the Benjamini-Hochberg method, with a false discovery rate (FDR) of less than 0.25. For serine and methylcytosine tracing studies, the percentage of ^{13}C incorporation was calculated using Microsoft Excel from peak areas and represented as bar graphs.

EAE Induction and Scoring

Active EAE was induced in female and male C57BL/6J mice⁷⁵ (10 weeks old) after pretreatment with either serine/glycine-free diet or control diet (Animal Specialty and Provisions, 1812281 and 1817070-209) for one week. MOG_{35–55} peptide dissolved in PBS at a concentration of 2 mg/mL was mixed 1:1 with complete Freund's adjuvant (8 mg/ml Tuberculin toxin in incomplete Freund's adjuvant), then mixed for 12 min into an emulsion. On day 0, mice were immunized by injecting

75 μ L of the emulsion subcutaneously into each of two sites on the lateral abdomen. In addition, on day 0 and again on day 2, mice were injected intraperitoneally with 375 ng pertussis toxin. Scoring was performed by a blinded individual according to the following scale: 0, no clinical deficit; 0.5, partial loss of tail tone; 1.0, complete tail paralysis or both partial loss of tail tone plus awkward gait; 1.5, complete tail paralysis and awkward gait; 2.0, tail paralysis with hind limb weakness evidenced by foot dropping between bars of cage lid while walking; 2.5, hind limb paralysis with little to no weight-bearing on hind limbs (dragging), but with some movement possible in legs; 3.0, complete hind limb paralysis with no movement in lower limbs; 3.5, hind limb paralysis with some weakness in forelimbs; 4.0, complete tetraplegia but with some movement of head; 4.5, moribund; and 5.0, dead.

RNA-Seq

For all experiments, RNA was isolated using the Qiagen RNeasy Mini Plus Kit. For RNA-seq, library preparation, sequencing, and demultiplexing was performed by Novogene. Raw FASTQ files were aligned to the murine reference genome with Kallisto⁷⁶. Library size normalization and differential expression was performed with DESeq2⁷⁷, Pathway enrichment analysis was performed with GSEA^{79,80}, and hypergeometric tests were performed with EnrichR⁸¹.

SCFEA Analysis

Re-analysis of publicly available data was performed by downloading the relevant dataset from the GEO repository or from figshare. Gene count matrices were extracted and then analyzed with the SCFEA python package or web server. The rate of de novo serine synthesis was estimated with the reaction titled “3PG → Serine.” Comparisons between groups was performed with either student’s t-test or Wilcoxon Rank sum test as described in the figure legends.

Bisulfite Conversion and Pyrosequencing

Bisulfite conversion was performed by EpigenDx according to standard pyrosequencing and Next Gen Sequencing protocols. Briefly, cell pellets were lysed based on the total cell count per sample and total volume received using M-digestion Buffer (ZymoResearch; Irvine, CA; cat# D5021-9) and 5-10 μ L of protease K (20mg/mL), with a final M-digestion concentration of 1X. The samples were incubated at 65°C for a minimum of 2 hours. For bisulfite modification, 20 μ L of the supernatant from the sample extracts was bisulfite modified using the EZ-96 DNA Methylation-Direct KitTM (ZymoResearch; Irvine, CA; cat# D5023) as per the manufacturer’s protocol. The bisulfite modified DNA samples were eluted using Melution buffer in 46 μ L. For Multiplex PCR, all bisulfite modified DNA samples were amplified using separate multiplex or simplex PCRs. PCRs included 0.5 units of HotStarTaq (Qiagen; Hilden, Germany; cat# 203205), 0.2 μ M primers, and 3 μ L of bisulfite-treated DNA in a 20 μ L reaction. All PCR products were verified using the Qiagen QIAxcel Advanced System (v1.0.6). Prior to library preparation, PCR products from the same sample were pooled and then purified using the QIAquick PCR Purification Kit columns or plates (cat# 28106 or 28183). The PCR cycling conditions were: 95°C 15 min; 45 x (95°C 30s; Ta°C 30 s; 68°C 30 s); 68°C 5 min; 4°C ∞ . Samples were run alongside established reference DNA samples with a range of methylation. They were created by mixing high- and low-methylated DNA to obtain samples with 0, 50, and 100% methylation. The high-methylated DNA was *in vitro* enzymatically methylated genomic DNA with >85% methylation. The low-methylated DNA was chemically and enzymatically treated with <5% methylation. They were first tested on numerous gene-specific and global methylation assays using pyrosequencing.

Methylation Sequencing

Libraries were prepared using a custom Library Preparation method created by EpigenDx. Next, library molecules were purified using Agencourt AMPure XP beads (Beckman Coulter; Brea, CA; cat# A63882). Barcoded samples were then pooled in an equimolar fashion before template

preparation and enrichment were performed on the Ion Chef™ system using Ion 520™ & Ion 530™ ExT Chef reagents (Thermo Fisher; Waltham, MA; cat# A30670). Following this, enriched, template-positive library molecules were sequenced on the Ion S5™ sequencer using an Ion 530™ sequencing chip (cat# A27764). FASTQ files from the Ion Torrent S5 server were aligned to a local reference database using the open-source Bismark Bisulfite Read Mapper program (v0.12.2) with the Bowtie2 alignment algorithm (v2.2.3). Methylation levels were calculated in Bismark by dividing the number of methylated reads by the total number of reads. An R-squared value (RSQ) was previously calculated from controls set at known methylation levels to test for PCR bias.

T-cell Transfer Model of Inflammatory Bowel Disease

To induce autoimmune colitis, CD4 T cells were transferred into RAG-knockout mice (Jackson Laboratories #002216). Briefly, CD4 cells were isolated from wild-type C57BL/6 mice and cultured in a mixture of 50% cRPMI (RPMI+10% Fetal Bovine Serum, 1 % penicillin-streptomycin, and 0.1% 2-Mercaptoethanol) and 50% AIM-V media with plate bound anti-CD3 stimulation (3 ug/mL) and anti-CD28 stimulation (2 ug/mL) along with 10 ng/mL murine IL-2. Cells were stimulated for 3 days, rested for 2 days, and then restimulated for 2 days. 10 million activated cells were then transferred into each mouse via i.p. injection. At the same time, naïve CD4 cells were cultured under Treg polarizing conditions as described above and 1 million cells were transferred into each mouse at the same time as the injection of the activated cells. Weights were recorded weekly until euthanasia.

Quantification and Statistical Analysis

All statistical analyses were performed using GraphPad Prism software, Python, or R studio. Details of statistical analyses for each experiment and/or data set can be found in the figures and figure legends. When cumulative data was tabulated from multiple independent experiments, experimental groups from each independent experiment were normalized to a matched control condition to allow integration across experiments. In these cases, in which there is no variability among matched control values, statistical analysis was performed with a non-parametric test as outlined in standard statistical guidelines (doi: 10.1111/bph.14153).

Acknowledgements

We kindly thank Matthew Smith, Payam Gharibani, Judy Lee, Erika Pearce, Ed Pearce, Brett Morrison, and Peter Calabresi for constructive comments and technical assistance. Additionally, we thank EpigenDx for their help with methylation NGS panels and pyrosequencing.

This work was supported by NIH/NINDS Grant K08NS104266, Conrad N. Hilton Foundation Marilyn Hilton Bridging Award for Physician Scientists Grant 17316, and a Herbert R. and Jeanne C. Mayer Foundation grant to MDK. WHG was supported by NIH MSTP Grant T32 GM136577 and a Careers in Immunology Fellowship Award from the American Association of Immunologists. Metabolomics and mass spectrometry work was supported by the following awards to NP: CPRIT Proteomics and Metabolomics Core Facility (RP210227), NIH (P30 CA125123), NIH (R01CA282282) and Dan L. Duncan Cancer Center.

Additional information

Author Contributions

Conceptualization, WHG and MDK; Investigation, WHG, XD, KC (General); CA, VP, AHMK (Mass Spectrometry); Formal Analysis, WHG, MDK (General); VP, AHMK, NP (Mass Spectrometry); Writing – Original Draft, WHG and MDK; Writing – Review & Editing, WHG, MDK, NP; Supervision, NP and MDK; Funding Acquisition, NP and MDK.

Additional files

Supplemental Figures [↗](#)

Table S1 [↗](#)

Table S2 [↗](#)

References

1. Patel C.H., Powell J.D 2017) **Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease** *Curr Opin Immunol* **46**:82–88 <https://doi.org/10.1016/J.COI.2017.04.006>
2. Buck M 2016) **Mitochondrial dynamics controls T cell fate through metabolic programming** *Cell* **166**:63–76
3. Chapman N.M., Chi H 2022) **Metabolic adaptation of lymphocytes in immunity and disease** *Immunity* **55**:14–30 <https://doi.org/10.1016/J.IMMUNI.2021.12.012>
4. Geltink R.I.K., Kyle R.L., Pearce E.L 2018) **Unraveling the Complex Interplay between T Cell Metabolism and Function** *Annu Rev Immunol* **36**:461–488 <https://doi.org/10.1146/annurev-immunol-042617-053019>
5. Kelly B., O'Neill L.A.J 2015) **Metabolic reprogramming in macrophages and dendritic cells in innate immunity** *Cell Research* **25**:771–784 <https://doi.org/10.1038/cr.2015.68>
6. Kornberg M.D 2020) **The immunologic Warburg effect: Evidence and therapeutic opportunities in autoimmunity** *Wiley Interdiscip Rev Syst Biol Med* **12** <https://doi.org/10.1002/WSBM.1486>
7. O'Neill L.A.J., Kishton R.J., Rathmell J 2016) **A guide to immunometabolism for immunologists** *Nature Reviews Immunology* **16**:553–565 <https://doi.org/10.1038/nri.2016.70>
8. Frauwirth K.A., Riley J.L., Harris M.H., Parry R. V., Rathmell J.C., Plas D.R., Elstrom R.L., June C.H., Thompson C.B 2002) **The CD28 signaling pathway regulates glucose metabolism** *Immunity* **16**:769–777 [https://doi.org/10.1016/S1074-7613\(02\)00323-0](https://doi.org/10.1016/S1074-7613(02)00323-0)
9. Cham C.M., Gajewski T.F 2005) **Glucose Availability Regulates IFN- γ Production and p70S6 Kinase Activation in CD8⁺ Effector T Cells** *The Journal of Immunology* **174**:4670–4677 <https://doi.org/10.4049/JIMMUNOL.174.8.4670>
10. Cham C.M., Driessens G., O'Keefe J.P., Gajewski T.F 2008) **Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8⁺ T cells** *Eur J Immunol* **38**:2438–2450 <https://doi.org/10.1002/EJI.200838289>
11. Wang R., Dillon C.P., Shi L.Z., Milasta S., Carter R., Finkelstein D., McCormick L.L., Fitzgerald P., Chi H., Munger J., et al. 2011) **The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation** *Immunity* **35**:871–882 <https://doi.org/10.1016/J.IM-MUNI.2011.09.021>
12. Chang C.-H 2013) **Posttranscriptional control of T cell effector function by aerobic glycolysis** *Cell* **153**:1239–1251
13. Macintyre A.N., Gerriets V.A., Nichols A.G., Michalek R.D., Rudolph M.C., Deoliveira D., Anderson S.M., Abel E.D., Chen B.J., Hale L.P., et al. 2014) **The Glucose Transporter Glut1 Is Selectively Essential for CD4 T Cell Activation and Effector Function** *Cell Metab* **20**:61–72 <https://doi.org/10.1016/J.CMET.2014.05.004>

14. Gerriets V.A., Kishton R.J., Nichols A.G., MacIntyre A.N., Inoue M., Ilkayeva O., Winter P.S., Liu X., Priyadharshini B., Slawinska M.E., et al. 2015) **Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation** *Journal of Clinical Investigation* **125**:194–207 <https://doi.org/10.1172/JCI76012>
15. Shi L.Z., Wang R., Huang G., Vogel P., Neale G., Green D.R., Chi H 2011) **HIF1 α -dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells** *Journal of Experimental Medicine* **208**:1367–1376 <https://doi.org/10.1084/jem.20110278>
16. Shi H., Chi H 2019) **Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity** *Front Immunol* **10** <https://doi.org/10.3389/FIMMU.2019.02716>
17. Angelin A., Gil-de-Gómez L., Dahiya S., Jiao J., Guo L., Levine M.H., Wang Z., Quinn W.J., Kopinski P.K., Wang L., et al. 2017) **Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments** *Cell Metab* **25**:1282–1293 <https://doi.org/10.1016/j.cmet.2016.12.018>
18. Ho P.C., Bihuniak J.D., MacIntyre A.N., Staron M., Liu X., Amezcua R., Tsui Y.C., Cui G., Micevic G., Perales J.C., et al. 2015) **Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses** *Cell* **162**:1217–1228 <https://doi.org/10.1016/j.cell.2015.08.012>
19. Wang H., Franco F., Tsui Y.C., Xie X., Trefny M.P., Zappasodi R., Mohmood S.R., Fernández-García J., Tsai C.H., Schulze I., et al. 2020) **CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors** *Nature Immunology* **21**:298–308 <https://doi.org/10.1038/s41590-019-0589-5>
20. Lim S.A., Wei J., Nguyen T.L.M., Shi H., Su W., Palacios G., Dhungana Y., Chapman N.M., Long L., Saravia J., et al. 2021) **Lipid signalling enforces functional specialization of Treg cells in tumours** *Nature* **591**:306–311 <https://doi.org/10.1038/s41586-021-03235-6>
21. Kishore M., Cheung K.C.P., Fu H., Bonacina F., Wang G., Coe D., Ward E.J., Colamattéo A., Jangani M., Baragetti A., et al. 2017) **Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis** *Immunity* **47**:875–889 <https://doi.org/10.1016/j.immuni.2017.10.017>
22. Angelin A., Gil-de-Gómez L., Dahiya S., Jiao J., Guo L., Levine M.H., Wang Z., Quinn W.J., Kopinski P.K., Wang L., et al. 2017) **Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments** *Cell Metab* **25**:1282–1293 <https://doi.org/10.1016/j.CMET.2016.12.018>
23. Michalek R.D., Gerriets V.A., Jacobs S.R., Macintyre A.N., MacIver N.J., Mason E.F., Sullivan S.A., Nichols A.G., Rathmell J.C 2011) **Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets** *The Journal of Immunology* **186**:3299–3303 <https://doi.org/10.4049/JIMMUNOL.1003613>
24. Gerriets V.A., Kishton R.J., Johnson M.O., Cohen S., Siska P.J., Nichols A.G., Warmoes M.O., De Cubas A.A., MacIver N.J., Locasale J.W., et al. 2016) **Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression** *Nature Immunology* **17**:1459–1466 <https://doi.org/10.1038/ni.3577>
25. Macintyre A.N., Gerriets V.A., Nichols A.G., Michalek R.D., Rudolph M.C., Deoliveira D., Anderson S.M., Abel E.D., Chen B.J., Hale L.P., et al. 2014) **The Glucose Transporter Glut1 Is**

Selectively Essential for CD4 T Cell Activation and Effector Function *Cell Metab* **20**:61–72 <https://doi.org/10.1016/j.CMET.2014.05.004>

26. Wei J., Long L., Yang K., Guy C., Shrestha S., Chen Z., Wu C., Vogel P., Neale G., Green D.R., et al. 2016) **Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis** *Nature Immunology* **17**:277–285 <https://doi.org/10.1038/ni.3365>
27. Scherlinger M., Pan W., Hisada R., Boulougoura A., Yoshida N., Vukelic M., Umeda M., Krish-field S., Tsokos M.G., Tsokos G.C 2022) **Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity** *Sci Adv* **8** <https://doi.org/10.1126/SCIADV.ADC9657>
28. Kornberg M.D., Bhargava P., Kim P.M., Putluri V., Snowman A.M., Putluri N., Calabresi P.A., Snyder S.H 2018) **Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity** *Science* **360**:449–453 <https://doi.org/10.1126/science.aan4665>
29. Gerriets V.A., Kishton R.J., Nichols A.G., MacIntyre A.N., Inoue M., Ilkayeva O., Winter P.S., Liu X., Priyadharshini B., Slawinska M.E., et al. 2015) **Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation** *J Clin Invest* **125**:194–207 <https://doi.org/10.1172/JCI76012>
30. De Rosa V., Galgani M., Porcellini A., Colamatteo A., Santopaolo M., Zuchegna C., Romano A., De Simone S., Procaccini C., La Rocca C., et al. 2015) **Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants** *Nature Immunology* **16**:1174–1184 <https://doi.org/10.1038/ni.3269>
31. Ubaid Ullah Andrabi, Tripathi S.B.A., Dirasantha S.K., Kanduri O., Rautio K., Gross S., Lehtimäki C.C., Bala S., Tuomisto K., et al. 2018) **Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells** *Cell Rep* **22**:2094–2106 <https://doi.org/10.1016/j.CELREP.2018.01.070>
32. Schafflick D., Xu C.A., Hartlehnert M., Cole M., Schulte-Mecklenbeck A., Lautwein T., Wolbert J., Heming M., Meuth S.G., Kuhlmann T., et al. 2020) **Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis** *Nature Communications* **11**:1–14 <https://doi.org/10.1038/s41467-019-14118-w>
33. Procaccini C., Carbone F., Di Silvestre D., Brambilla F., De Rosa V., Galgani M., Faicchia D., Marone G., Tramontano D., Corona M., et al. 2016) **The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements** *Immunity* **44**:406–421 <https://doi.org/10.1016/j.IMMUNI.2016.01.028>
34. Li X., Tang S., Wang Q.Q., Leung E.L.H., Jin H., Huang Y., Liu J., Geng M., Huang M., Yuan S., et al. 2017) **Identification of Epigallocatechin-3-Gallate as an Inhibitor of Phosphoglycerate Mutase 1** *Front Pharmacol* **8** <https://doi.org/10.3389/FPHAR.2017.00325>
35. Dykema A.G., Zhang J., Cheung L.S., Connor S., Zhang B., Zeng Z., Cherry C.M., Li T., Caushi J.X., Nishimoto M., et al. 2023) **Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response** *Sci Immunol* **8** <https://doi.org/10.1126/SCIIMMUNOL.ADG1487>
36. Dimauro S., Miranda A.F., Khan S., Gitlin K., Friedman R 1981) **Human Muscle Phosphoglycerate Mutase Deficiency: Newly Discovered Metabolic Myopathy** *Science* **212** <https://doi.org/10.1126/SCIENCE.6262916>

37. Koo B., Oskarsson B (2016) **Phosphoglycerate mutase deficiency (glycogen storage disease X) caused by a novel variant in PGAM-M** *Neuromuscular Disorders* **26**:688–690 <https://doi.org/10.1016/j.NMD.2016.08.002>
38. Lunt S.Y., Vander Heiden M.G (2011) **Aerobic glycolysis: meeting the metabolic requirements of cell proliferation** *Annu Rev Cell Dev Biol* **27** <https://doi.org/10.1146/annurev-cellbio-092910-154237>
39. He L., Ding Y., Zhou X., Li T., Yin Y (2023) **Serine signaling governs metabolic homeostasis and health** *Trends in Endocrinology and Metabolism* **34**:361–372 <https://doi.org/10.1016/j.tem.2023.03.001>
40. Ron-Harel N., Santos D., Ghergurovich J.M., Sage P.T., Reddy A., Lovitch S.B., Dephore N., Satterstrom F.K., Sheffer M., Spinelli J.B., et al. (2016) **Mitochondrial Biogenesis and Proteome Remodeling Promote One-Carbon Metabolism for T Cell Activation** *Cell Metab* **24**:104–117 <https://doi.org/10.1016/j.cmet.2016.06.007>
41. Ma E.H., Bantug G., Griss T., Condotta S., Johnson R.M., Samborska B., Mainolfi N., Suri V., Guak H., Balmer M.L., et al. (2017) **Serine Is an Essential Metabolite for Effector T Cell Expansion** *Cell Metab* **25**:345–357 <https://doi.org/10.1016/j.cmet.2016.12.011>
42. Kurniawan H., Franchina D.G., Guerra L., Bonetti L., Baguet L.S., Grusdat M., Schlicker L., Hunewald O., Dostert C., Merz M.P., et al. (2020) **Glutathione Restricts Serine Metabolism to Preserve Regulatory T Cell Function** *Cell Metab* **31**:920–936 <https://doi.org/10.1016/j.cmet.2020.03.004>
43. Bojkova D., Reus P., Panosch L., Bechtel M., Rothenburger T., Kandler J.D., Pfeiffer A., Wagner J.U.G., Shumliakivska M., Dimmeler S., et al. (2023) **Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform** *iScience* **26** <https://doi.org/10.1016/j.ISCI.2023.105944>
44. Pacold M.E., Brimacombe K.R., Chan S.H., Rohde J.M., Lewis C.A., Swier L.J.Y.M., Possemato R., Chen W.W., Sullivan L.B., Fiske B.P., et al. (2016) **A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate** *Nature Chemical Biology* **2016** <https://doi.org/10.1038/nchembio.2070>
45. Alghamdi N., Chang W., Dang P., Lu X., Wan C., Gampala S., Huang Z., Wang J., Ma Q., Zang Y., et al. (2021) **A graph neural network model to estimate cell-wise metabolic flux using single-cell RNA-seq data** *Genome Res* **31**:1867–1884 <https://doi.org/10.1101/GR.271205.120/-/DC1>
46. Tuong Z.K., Loudon K.W., Berry B., Richoz N., Jones J., Tan X., Nguyen Q., George A., Hori S., Field S., et al. (2021) **Resolving the immune landscape of human prostate at a single-cell level in health and cancer** *Cell Rep* **37** <https://doi.org/10.1016/j.CELREP.2021.110132>
47. Camps J., Noël F., Liechti R., Massenet-Regad L., Rigade S., Götz L., Hoffmann C., Amblard E., Saichi M., Ibrahim M.M., et al. (2023) **Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUCan Database** *Cancer Res* **83**:363–373 <https://doi.org/10.1158/0008-5472.CAN-22-0074>
48. Reina-Campos M., Diaz-Meco M.T., Moscat J (2020) **The complexity of the serine glycine one-carbon pathway in cancer** *Journal of Cell Biology* **219** <https://doi.org/10.1083/JCB.201907022/132493>

49. Makino Y., Oe C., Iwama K., Suzuki S., Nishiyama A., Hasegawa K., Okuda H., Hirata K., Ueno M., Kawaji K., et al. 2022) **Serine hydroxymethyltransferase as a potential target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors** *Communications Biology* **2022** <https://doi.org/10.1038/s42003-022-03555-x>
50. Ducker G.S., Ghergurovich J.M., Mainolfi N., Suri V., Jeong S.K., Li S.H.J., Friedman A., Manfredi M.G., Gitai Z., Kim H., et al. 2017) **Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma** *Proc Natl Acad Sci U S A* **114**:11404–11409 <https://doi.org/10.1073/PNAS.1706617114>
51. Maddocks O.D.K., Labuschagne C.F., Adams P.D., Vousden K.H 2016) **Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells** *Mol Cell* **61**:210–221 <https://doi.org/10.1016/J.MOLCEL.2015.12.014>
52. Mentch S.J., Locasale J.W 2016) **One-carbon metabolism and epigenetics: understanding the specificity** *Ann N Y Acad Sci* **1363**:91–98 <https://doi.org/10.1111/NYAS.12956>
53. Polansky J.K., Kretschmer K., Freyer J., Floess S., Garbe A., Baron U., Olek S., Hamann A., von Boehmer H., Huehn J 2008) **DNA methylation controls Foxp3 gene expression** *Eur J Immunol* **38**:1654–1663 <https://doi.org/10.1002/EJI.200838105>
54. Jeong S.Y., Ahn S.G., Lee J.H., Kim H.S., Kim J.W., Rhim H., Jeong S.W., Kim I.K 1999) **3-Deazaadenosine, a S-adenosylhomocysteine hydrolase inhibitor, has dual effects on NF- κ B regulation: Inhibition of NF- κ B transcriptional activity and promotion of I κ B α degradation** *Journal of Biological Chemistry* **274**:18981–18988 <https://doi.org/10.1074/jbc.274.27.18981>
55. Michalek R.D., Gerriets V.A., Jacobs S.R., Macintyre A.N., MacIver N.J., Mason E.F., Sullivan S.A., Nichols A.G., Rathmell J.C 2011) **Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4⁺ T Cell Subsets** *The Journal of Immunology* **186**:3299–3303 <https://doi.org/10.4049/JIMMUNOL.1003613>
56. Macintyre A.N., Gerriets V.A., Nichols A.G., Michalek R.D., Rudolph M.C., Deoliveira D., Anderson S.M., Abel E.D., Chen B.J., Hale L.P., et al. 2014) **The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function** *Cell Metab* **20**:61–72 <https://doi.org/10.1016/j.cmet.2014.05.004>
57. Shi L.Z., Wang R., Huang G., Vogel P., Neale G., Green D.R., Chi H 2011) **HIF1 α -dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells** *Journal of Experimental Medicine* **208**:1367–1376 <https://doi.org/10.1084/JEM.20110278>
58. Lee J., Walsh M.C., Hoehn K.L., James D.E., Wherry E.J., Choi Y 2014) **Regulator of Fatty Acid Metabolism, Acetyl Coenzyme A Carboxylase 1, Controls T Cell Immunity** *The Journal of Immunology* **192**:3190–3199 <https://doi.org/10.4049/jimmunol.1302985>
59. Berod L., Friedrich C., Nandan A., Freitag J., Hagemann S., Harmrolfs K., Sandouk A., Hesse C., Castro C.N., Bähr H., et al. 2014) **De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells** *Nat Med* **20** <https://doi.org/10.1038/nm.3704>
60. Tanimine N., Germana S.K., Fan M., Hippen K., Blazar B.R., Markmann J.F., Turka L.A., Priyadharshini B 2019) **Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets** *PLoS One* **14** <https://doi.org/10.1371/JOUR-NAL.PONE.0217761>

61. Patel C.H., Leone R.D., Horton M.R., Powell J.D 2019) **Targeting metabolism to regulate immune responses in autoimmunity and cancer** *Nature Reviews Drug Discovery* **18**:669–688 <https://doi.org/10.1038/s41573-019-0032-5>
62. McPhedran S.J., Carleton G.A., Lum J.J 2024) **Metabolic engineering for optimized CAR-T cell therapy** *Nature Metabolism* **6**:396–408 <https://doi.org/10.1038/s42255-024-00976-2>
63. Nanjireddy P.M., Olejniczak S.H., Buxbaum N.P 2023) **Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes** *Front Immunol* **14** <https://doi.org/10.3389/FIMMU.2023.1121565>
64. Chan J.D., Scheffler C.M., Munoz I., Sek K., Lee J.N., Huang Y.-K., Yap K.M., Saw N.Y.L., Li J., Chen A.X.Y., et al. 2024) **FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy** *Nature* **2024**:1–10 <https://doi.org/10.1038/s41586-024-07242-1>
65. Good Z., Spiegel J.Y., Sahaf B., Malipatlolla M.B., Ehlinger Z.J., Kurra S., Desai M.H., Reynolds W.D., Wong Lin A., Vandris P., et al. 2022) **Post-infusion CAR Treg cells identify patients resistant to CD19-CAR therapy** *Nature Medicine* **28**:1860–1871 <https://doi.org/10.1038/s41591-022-01960-7>
66. Zhang Q., Lu W., Liang C.L., Chen Y., Liu H., Qiu F., Dai Z 2018) **Chimeric antigen receptor (CAR) Treg: A promising approach to inducing immunological tolerance** *Front Immunol* **9** <https://doi.org/10.3389/FIMMU.2018.02359f>
67. Abraham A.R., Maghsoudlou P., Copland D.A., Nicholson L.B., Dick A.D 2023) **CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions** *Frontiers in Ophthalmology* **3** <https://doi.org/10.3389/FOPHT.2023.1184937>
68. Toriyama K., Kuwahara M., Kondoh H., Mikawa T., Takemori N., Konishi A., Yorozyu T., Yamada T., Soga T., Shiraishi A., et al. 2020) **T cell-specific deletion of Pgam1 reveals a critical role for glycolysis in T cell responses** *Communications Biology* **3**:1–13 <https://doi.org/10.1038/s42003-020-01122-w>
69. Itoyama R., Yasuda-Yoshihara N., Kitamura F., Yasuda T., Bu L., Yonemura A., Uchihara T., Arima K., Hu X., Jun Z., et al. 2021) **Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer** *Cancer Lett* **523**:29–42 <https://doi.org/10.1016/j.CANLET.2021.09.007>
70. Zafari P., Yari K., Mostafaei S., Iranshahi N., Assar S., Fekri A., Taghadosi M 2018) **Analysis of Helios gene expression and Foxp3 TSDR methylation in the newly diagnosed Rheumatoid Arthritis patients** *Immunol Invest* **47**:632–642 <https://doi.org/10.1080/08820139.2018.1480029>
71. Toker A., Engelbert D., Garg G., Polansky J.K., Floess S., Miyao T., Baron U., Düber S., Geffers R., Giehr P., et al. 2013) **Active Demethylation of the Foxp3 Locus Leads to the Generation of Stable Regulatory T Cells within the Thymus** *The Journal of Immunology* **190**:3180–3188 <https://doi.org/10.4049/JIMMUNOL.1203473>
72. Polansky J.K., Kretschmer K., Freyer J., Floess S., Garbe A., Baron U., Olek S., Hamann A., von Boehmer H., Huehn J. 2008) **DNA methylation controls Foxp3 gene expression** *Eur J Immunol* **38**:1654–1663 <https://doi.org/10.1002/EJI.200838105>
73. Kressler C., Gasparoni G., Nordström K., Hamo D., Salhab A., Dimitropoulos C., Tierling S., Reinke P., Volk H.D., Walter J., et al. 2021) **Targeted De-Methylation of the FOXP3-TSDR Is**

74. Sugiura A., Andrejeva G., Voss K., Heintzman D.R., Xu X., Madden M.Z., Ye X., Beier K.L., Chowdhury N.U., Wolf M.M., et al. 2022) **MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function** *Immunity* **55**:65–81 <https://doi.org/10.1016/j.immuni.2021.10.011>
75. Godfrey W.H., Hwang S., Gharibani P., Abramson E., , and, Kornberg M.D. 2022) **Therapeutic Potential of Blocking GAPDH Nitrosylation with CGP3466b in Experimental Autoimmune Encephalomyelitis** *bioRxiv* <https://doi.org/10.1101/2022.08.31.505712>
76. Bray N.L., Pimentel H., Melsted P., Pachter L 2016) **Near-optimal probabilistic RNA-seq quantification** *Nature Biotechnology* **34**:525–527 <https://doi.org/10.1038/nbt.3519>
77. Love M.I., Huber W., Anders S 2014) **Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2** *Genome Biol* **15**:1–21 <https://doi.org/10.1186/S13059-014-0550-8>
78. Muzellec B., Teleńczuk M., Cabeli V., Andreux M 2023) **PyDESeq2: a python package for bulk RNA-seq differential expression analysis** *Bioinformatics* **39** <https://doi.org/10.1093/bioinformatics/btad547>
79. Reimand J., Isserlin R., Voisin V., Kucera M., Tannus-Lopes C., Rostamianfar A., Wadi L., Meyer M., Wong J., Xu C., et al. 2019) **Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap** *Nature Protocols* **14**:482–517 <https://doi.org/10.1038/s41596-018-0103-9>
80. Fang Z., Liu X., Peltz G 2023) **GSEAPy: a comprehensive package for performing gene set enrichment analysis in Python** *Bioinformatics* **39** <https://doi.org/10.1093/bioinformatics/btac757>
81. Kuleshov M. V., Jones M.R., Rouillard A.D., Fernandez N.F., Duan Q., Wang Z., Koplev S., Jenkins S.L., Jagodnik K.M., Lachmann A., et al. 2016) **Enrichr: a comprehensive gene set enrichment analysis web server 2016 update** *Nucleic Acids Res* **44** <https://doi.org/10.1093/nar/gkw377>

Author information

Wesley H Godfrey

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, United States

Kaho Cho

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, United States

Xiaoqing Deng

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, United States

Chandra Shekar R Ambati

Advanced Technology Core, Baylor College of Medicine, Houston, United States

Vasanta Putluri

Advanced Technology Core, Baylor College of Medicine, Houston, United States

Abu Hena Mostafa Kamal

Advanced Technology Core, Baylor College of Medicine, Houston, United States, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States

Nagireddy Putluri

Advanced Technology Core, Baylor College of Medicine, Houston, United States, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States

Michael D Kornberg

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, United States

ORCID iD: [0000-0003-2588-7325](https://orcid.org/0000-0003-2588-7325)

For correspondence: michael.kornberg@jhmi.edu

Editors

Reviewing Editor

Sameh Ali

Children's Cancer Hospital Egypt, Cairo, Egypt

Senior Editor

Betty Diamond

The Feinstein Institute for Medical Research, Manhasset, United States of America

Reviewer #1 (Public review):

Summary:

This work provides a new potential tool to manipulate Tregs function for therapeutic use. It focuses on the role of PGAM in Tregs differentiation and function. The authors, interrogating publicly available transcriptomic and proteomic data of human regulatory T cells and CD4 T cells, state that Tregs express higher levels of PGAM (at both message and protein levels) compared to CD4 T cells. They then inhibit PGAM by using a known inhibitor ECGC and show that this inhibition affects Tregs differentiation. This result was also observed when they used antisense oligonucleotides (ASOs) to knockdown PGAM1.

PGAM1 catalyzes the conversion of 3PG to 2PG in the glycolysis cascade. However, the authors focused their attention on the additional role of 3PG: acting as starting material for the de novo synthesis of serine.

They hypothesized that PGAM1 regulates Tregs differentiation by regulating the levels of 3PG that are available for de novo synthesis of serine, which has a negative impact on Tregs differentiation. Indeed, they tested whether the effect on Tregs differentiation observed by reducing PGAM1 levels was reverted by inhibiting the enzyme that catalyzes the synthesis of serine from 3PG.

The authors continued by testing whether both synthesized and exogenous serine affect Tregs differentiation and continued with *in vivo* experiments to examine the effects of dietary serine restriction on Tregs function.

In order to understand the mechanism by which serine impacts Tregs function, the authors assessed whether this depends on the contribution of serine to one-carbon metabolism and to DNA methylation.

The authors therefore propose that extracellular serine and serine whose synthesis is regulated by PGAM1 induce methylation of genes Tregs associated, downregulating their expression and overall impacting Tregs differentiation and suppressive functions.

Strengths:

The strength of this paper is the number of approaches taken by the authors to verify their hypothesis. Indeed, by using both pharmacological and genetic tools in *in vitro* and *in vivo* systems they identified a potential new metabolic regulation of Tregs differentiation and function.

Weaknesses:

Using publicly available transcriptomic and proteomic data of human T cells, the authors claim that both *ex vivo* and *in vitro* polarized Tregs express higher levels of PGAM1 protein compared to CD4 T cells (naïve or cultured under Th0 polarizing conditions). The experiments shown in this paper have all been carried out in murine Tregs. Publicly available resources for murine data (ImmGen -RNAseq and ImmPres - Proteomics) however show that Tregs do not express higher PGAM1 (mRNA and protein) compared to CD4 T cells. It would be good to verify this in the system/condition used in the paper.

It would also be good to assess the levels of both PGAM1 mRNA and protein in Tregs PGAM1 knockdown compared to scramble using different methods e.g. qPCR and western blot. However, due to the high levels of cell death and differentiation variability, that would require cells to be sorted.

It is not specified anywhere in the paper whether cells were sorted for bulk experiments. Based on the variability of cell differentiation, it would be good if this was mentioned in the paper as it could help to interpret the data with a different perspective.

<https://doi.org/10.7554/eLife.104423.1.sa1>

Reviewer #2 (Public review):

Summary:

The authors have tried to determine the regulatory role of Phosphoglycerate mutase (PGAM), an enzyme involved in converting 3-phosphoglycerate to 2-phosphoglycerate in glycolysis, in differentiation and suppressive function of regulatory CD4 T cells through *de novo* serine synthesis. This is done by contributing one carbon metabolism and eventually epigenetic regulation of Treg differentiation.

Strengths:

The authors have rigorously used inhibitors and antisense RNA to verify the contribution of these pathways in Treg differentiation *in-vitro*. This has also been verified in an *in-vivo* murine model of autoimmune colitis. This has further clinical implications in autoimmune disorders and cancer.

Weaknesses:

The authors have used inhibitors to study pathways involved in Treg differentiation. However, they have not studied the context of overexpression of PGAM, which was the actual reason to pursue this study.

<https://doi.org/10.7554/eLife.104423.1.sa0>